



Tata Elxsi Ltd

Q1FY26



Tata Elxsi Ltd.

Margin clouds persist as recovery trails expectations

CMP* INR 6,066	Target INR 4,965	Potential Upside (18.2%)	Market Cap (INR Mn) INR 377,820	Recommendation SELL	Sector Internet Software & Services
--------------------------	----------------------------	------------------------------------	---	-------------------------------	---

Result Highlights

Revenue:

Tata Elxsi's Q1FY26 revenue stood at INR 8,921 Mn. (-1.8% QoQ/ -3.7% YoY), below our estimates by 5.5%, led by broad-based weakness across verticals. Further, it reported revenue decline of 3.9% QoQ CC (-9.0% YoY CC), led by macroeconomic headwinds, coupled with industry-specific and client-side challenges that weighed on R&D budgets and decision-making cycles across key markets.

Margins and Profitability:

EBIT stood at INR 1,624 Mn. (-11.2% QoQ/ -27.9% YoY), driven by muted revenue performance and unfavorable currency movement impacting on-site salary expenses. Consequently, EBIT margin contracted by 610bps YoY (-193bps QoQ) to 18.2%. Net profit stood at INR 1,444 Mn. (-16.3% QoQ/ -21.6% YoY), while its net margin contracted by 369bps YoY to 16.2% (-280bps QoQ), lowest in 21 quarters.

Vertical Performance:

Transportation segment reported a decline of 5.3% YoY CC (+0.0% QoQ CC). The sequential recovery **was driven by ramp-up in execution of large Software Defined Vehicle (SDV) engagements** with marquee clients such as Mercedes-Benz, a European OEM, and Suzuki. **Healthcare and Lifesciences segment posted a decline of 13.5% CC YoY (-6.7% QoQ CC),** impacted by two primary factors: (i) tariff-related disruptions that affected ongoing medical device engineering programs, and (ii) delayed ramp-up of new projects from two large US-based clients, who opted to pause discretionary spend due to prevailing uncertainties in their own businesses.

Demand Drivers:

The **automotive industry is expected to consolidate and remain in transition due to persistent uncertainties** related to **China operations** and **evolving tariff regimes weighing on OEM** and supplier R&D allocation decisions. Concurrently, the Tier-1 supplier segment continues to face structural headwinds, limiting near-term visibility on engineering spend and program ramp-ups. Management indicated that the vertical's growth trajectory is expected to strengthen in the ensuing quarters, supported by a healthy deal pipeline and expansion of strategic accounts. Despite the subdued quarterly performance, **management remains optimistic about a gradual recovery starting from Q2FY26E.**

Valuation and Outlook:

We have **revised out FY26E/FY27E EPS estimates by -28.1%/-25.9%** on account of **slower-than-anticipated recovery in media and healthcare, weak revenue visibility, and a delayed margin normalization trajectory**, with EBIT margins now expected to remain below FY25 levels over near to medium term. **Persistent macro headwinds and muted vertical traction warrant a cautious stance** until greater clarity emerges on growth and profitability recovery.


We value Tata Elxsi at a 38.0x Jun'27 EPS, implying a target price of INR 4,965, as we roll forward our valuation to Q1FY28E. We downgrade our rating from "HOLD" to "SELL" as we adopt a cautious outlook until clearer evidence of sustainable growth and profitability improvement emerges.

KEY FINANCIALS

INR Millions	FY24	FY25	FY26E	FY27E	FY28E
Revenue	35,521	37,290	37,212	41,876	47,123
EBIT	9,470	8,681	7,141	8,952	10,629
EBIT Margin	26.7%	23.3%	19.2%	21.4%	22.6%
PAT	7,922	7,849	6,371	7,835	9,094
EPS	127.2	126.0	102.3	125.8	146.0

Source: Company, DevenChoksey Research

SHARE PRICE PERFORMANCE



MARKET DATA

Shares outs (Mn.)	62
Mkt Cap (INR Mn.)	377,820
52-Week H/L (INR)	9,080/4,700
3M Volume Avg (In '000)	278
Face Value (INR)	10
Bloomberg Code	TELX IN

*Based on previous closing

Note: All the market data is as of previous closing

SHARE HOLDING PATTERN (%)

Particulars (%)	Mar-25	Dec-24	Sep-24
Promoters	43.9	43.9	43.9
FIIIs	12.7	13.3	13.7
DIIIs	8.5	7.5	7.4
Others	34.9	35.3	35.0
Total	100.0	100.0	100.0

6.0%

Revenue CAGR
between FY25-27E

-0.1%

Adj. PAT CAGR
between FY25-27E

Tata Elxsi Ltd.

Key Concall Highlights:

Media & communications: navigating structural shifts, poised for recovery

- Tata Elxsi's media and communications vertical remained under pressure in Q1FY26, reflecting continued structural challenges in the global media and telecom landscape. Management noted that the industry has been grappling with stagnating subscriber growth, declining ARPUs, and the aftereffects of overexpansion during the COVID period.
- Telecom segment which had observed heavy investments in 5G have not yet translated into meaningful revenue streams, prompting a renewed focus on cost rationalization, open-source adoption, and automation. Tata Elxsi is actively positioning its proprietary automation platform, Neuron, to help clients achieve higher operational efficiency through GenAI-led frameworks.
- Management indicated that the transition costs linked to large deal wins are now largely absorbed, and these deals are expected to ramp up meaningfully from Q2FY26E onward. Coupled with a healthy deal pipeline and differentiated offerings, the vertical is positioned for sequential recovery, with medium-term growth contingent on broader industry stabilization and enterprise investment revival.

System integration: lumpy by nature, no structural concern

- The sharp sequential decline of 36.4% QoQ to INR 196 Mn in Tata Elxsi's system integration and support (SIS) segment during Q1FY26 was attributed to a high base effect from the previous quarter, which included a one-time, large-value project. Specifically, the spike in Q4FY25 was driven by a marquee experiential design engagement for the Bharat Pavilion at the World Expo 2025 in Osaka, valued at approximately INR 130–140 Mn.
- Management indicated that the segment inherently operates with project-based volatility, and these engagements, often ranging between INR 100–200 Mn. with quick execution cycles of three to four months, can lead to sharp fluctuations in reported revenue depending on closure timelines. The current quarter's dip, therefore, reflects timing mismatches rather than any fundamental weakness in the business.
- While some similar deals were in the pipeline during Q1, closure timelines spilled over, leading to a shortfall in reported numbers. Management expects the segment to normalize around a quarterly run-rate of INR 250–300 Mn and emphasized that percentage swings should be viewed in context given the relatively small base. No material decline is expected going forward, and performance will remain tied to the timing and conversion of discrete project wins.

Margin Profile

- EBIT margin contracted by 610bps YoY to 18.2%, led by decline in revenue and adverse currency impact on on-site salary costs. Management anticipates a gradual margin recovery over the next three quarters, although full-year margins are expected to remain below the prior year's levels. In response, the company is actively pursuing operational efficiencies to offset the impact. Notably, the aerospace and defense vertical is expected to contribute positively, with deal wins projected at sustainable margins.

Headcount declines; attrition inches 170bps sequentially

- The headcount declined by 287 employees sequentially to 12,127 (-1,015 YoY), while the attrition rate inched upwards by 170bps QoQ to 15.0%. The management highlighted that they might roll wage hikes for junior employees starting from Q3FY26E.

Transportation to drive FY26E growth; Media recovery in sight, healthcare remains cautious bet





- Tata Elxsi expects FY26E growth to be led by its Transportation segment, backed by strong deal momentum and sustained market traction. The Media & Communication vertical is anticipated to recover, with growth likely resuming from Q2FY26E onwards.
- However, the Healthcare segment remains a cautious area due to tariff challenges and a limited client base among which two of the clients have already paused their discretionary spending. Despite strategic investments in sales and leadership, growth in Healthcare is expected to be gradual, with a potential uptick in H2FY26E given the long sales cycles and delayed closures in this vertical.

OEM Vs Tier-1

- Management noted that OEM clients have shown stronger intent to invest, particularly in software-defined vehicle (SDV) programs
- In contrast, the Tier-1 supplier segment continues to face pressure, with slower conversion cycles and muted demand. Management acknowledged that this cohort has been more cautious in spending, reflecting macro uncertainties and inventory normalization
- From a pipeline standpoint, OEM-led deal visibility remains robust, and the company expects this segment to drive the majority of transportation vertical growth in the coming quarters
- As a result, while OEM-driven business is expected to lead recovery and growth in H2FY26E, the Tier-1 segment may continue to lag until there is greater clarity on demand normalization and investment appetite.

Tata Elxsi Ltd.

STORY IN CHARTS




Source: Company, DevenChoksey Research

Tata Elxsi Ltd.


RESULT SNAPSHOT

Particulars (INR Mn)	Q1FY26	Q4FY25	Q1FY25	QoQ	YoY
Revenue from Operations	8,921	9,083	9,265	(1.8%)	(3.7%)
Cost of Materials Consumed	665	742	504	(10.3%)	32.0%
Employee benefits expenses	5,291	5,176	4,985	2.2%	6.1%
Other Expenses	1,097	1,089	1,253	0.7%	(12.4%)
Total Expenses	7,054	7,007	6,742	0.7%	4.6%
EBITDA	1,867	2,077	2,523	(10.1%)	(26.0%)
EBITDA margin (%)	20.9%	22.9%	27.2%	(193bps)	(630bps)
Depreciation and Amortization	243	247	271	(1.7%)	(10.3%)
EBIT	1,624	1,830	2,252	(11.2%)	(27.9%)
EBIT margin (%)	18.2%	20.1%	24.3%	(193bps)	(610bps)
Finance Costs	46	46	49	(0.6%)	(6.8%)
Other Income	385	431	321	(10.7%)	19.9%
Exceptional Items	0	0	0	NA	NA
Profit before tax	1,963	2,214	2,524	(11.3%)	(22.2%)
Tax Expense	520	490	683	6.0%	(23.9%)
Net profit	1,444	1,724	1,841	(16.3%)	(21.6%)
Net profit (%)	16.2%	19.0%	19.9%	(280bps)	(369bps)
Diluted EPS (INR)	23.2	27.7	29.6	(16.3%)	(21.6%)

Source: Company, DevenChoksey Research



Source: Company, DevenChoksey Research



Tata Elxsi Ltd.

Change in Estimates:

Tata Elxsi's delivered a subdued performance in Q1FY26 amidst a challenging macro environment. Revenue growth was **impacted by slower decision-making cycles, client-specific delays, and muted discretionary spending across key verticals**. OEM clients continued to invest, while Tier-1 accounts remained cautious, leading to a divergence in demand momentum. The company also secured additional strategic wins in this space, reinforcing visibility for H2FY26E.

Media and communications **remained under pressure due to structural industry challenges and delayed deal ramp-ups**. Healthcare and Lifesciences saw temporary setbacks due to tariff-related disruptions and project pauses by two large US clients. However, the company onboarded new logos in this segment and anticipates a stronger second half as these engagements scale. **Management has indicated a slower-than-expected recovery in both the media and healthcare verticals, with improvement now expected to be more gradual than previously guided**. Additionally, the company expects to close FY26E with EBIT margins below FY25 levels, reflecting the impact of weak revenue traction and the delayed benefit of operating leverage.

Given the persistence of global macro headwinds and vertical-specific softness, we revise our estimates of FY26E/FY27E EPS by -28.1%/-25.9%, respectively. These revisions are driven by lower visibility on topline acceleration and a more extended margin normalization trajectory, with EBIT margins now expected to recover at a slower pace and likely to remain below FY25 benchmarks for a longer period.

	New Estimates			Old Estimates			Variation		
	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
Revenue	37,212	41,876	47,123	41,850	48,191	NA	-11.1%	-13.1%	NM
EBIT	7,141	8,952	10,629	10,289	12,487	NA	-30.6%	-28.3%	NM
PAT	6,371	7,835	9,094	8,861	10,574	NA	-28.1%	-25.9%	NM
EPS	102.3	125.8	146.0	142.3	169.8	NA	-28.1%	-25.9%	NM
EBIT (%)	19.2%	21.4%	22.6%	24.6%	25.9%	NA	-540bps	-453bps	NM
PAT (%)	17.1%	18.7%	19.3%	21.2%	21.9%	NA	-405bps	-323bps	NM

Valuation:





We value Tata Elxsi at a 38.0x Jun'27 EPS, implying a target price of INR 4,965, as we roll forward our valuation to Q1FY28E. We downgrade our rating from "HOLD" to "SELL" as we adopt a cautious outlook until clearer evidence of sustainable growth and profitability improvement emerges.

Company	CMP	MCAP	Revenue	EPS	EBIT	P/E		FCF Yield (%)		RoE(%)	
			CAGR	CAGR	Margin (%)						
	INR	INR Bn	FY25-27E (%)	FY25-27E (%)	FY25	FY26E	FY27E	FY26E	FY27E	FY26E	FY27E
Tata Elxsi	6,066	377.8	6.0%	-0.1%	23.3%	60	48.8	1.3	1.2	20.5	22.9
Domestic Peers											
Coforge	1,888	626.3	21.9%	38.5%	12.4%	44.1	35.4	1.8	2.8	20.3	22.0
KPIT Tech	1,253	347.3	14.6%	15.4%	17.2%	39.8	32.9	2.3	2.9	27.0	27.1
Mphasis	2,861	542.6	8.3%	12.4%	15.3%	28.6	25.2	3.6	3.7	19.0	20.0
Newgen Software	1,105	156.9	18.8%	19.5%	22.6%	43.1	35.1	NA	NA	21.3	21.7
Mean			15.9%	21.4%	16.9%	38.9x	32.2x	2.6%	3.1%	21.9%	22.7%
Median			16.7%	17.5%	16.3%	41.5x	34.0x	2.3%	2.9%	20.8%	21.9%

Source: Company, DevenChoksey Research

Tata Elxsi Ltd.

Valuation Charts:



Source: Bloomberg, DevenChoksey Research

Tata Elxsi Ltd.

KEY FINANCIALS

Exhibit 1: Profit & Loss Statement

INR Mn	FY25	FY26E	FY27E	FY28E
Revenue	37,290	37,212	41,876	47,123
Total Operating expenses	27,561	29,011	31,720	35,134
EBITDA	9,729	8,202	10,156	11,990
Depreciation	1,049	1,061	1,204	1,360
EBIT	8,681	7,141	8,952	10,629
Finance Cost & Extra Ordinary- Expense	190	193	204	220
Other income, net	1,793	1,674	1,839	1,880
Pre-tax Income	10,284	8,622	10,587	12,289
Income tax expense	2,435	2,251	2,753	3,195
Net profit	7,849	6,371	7,835	9,094
Diluted EPS (INR)	126.0	102.3	125.8	146.0
Shares in Mn	62.3	62.3	62.3	62.3

Exhibit 3: Cash Flow Statement

INR Millions	FY25	FY26E	FY27E	FY28E
CFFO	8,120	6,160	5,768	7,079
CFFI	-3,083	465	478	349
CFFF	-4,986	-3,795	-4,786	-5,944
Net Inc/Dec	51	2,830	1,460	1,484
Opening Cash	1,332	1,353	4,183	5,643
Exchange Rate Difference	-31	0	0	0
Closing Cash	1,353	4,183	5,643	7,127

Exhibit 4: Key Ratios

Key Ratios	FY25	FY26E	FY27E	FY28E
EBIT Margin (%)	23.3%	19.2%	21.4%	22.6%
Tax rate (%)	23.7%	26.1%	26.0%	26.0%
Net Profit Margin (%)	21.0%	17.1%	18.7%	19.3%
RoE (%)	27.4%	20.5%	22.9%	24.3%
RoCE (%)	28.4%	21.4%	24.4%	26.5%
P/E (x)	41.4x	60.0x	48.8x	42.0x

Source: Company, DevenChoksey Research

Exhibit 2: Balance Sheet

INR Millions	FY25	FY26E	FY27E	FY28E
Equity Share Capital	623	623	623	623
Other Equity	27,977	30,525	33,659	36,842
Total Equity	28,600	31,148	34,282	37,465
Deferred Tax Liability, (Net)	0	0	0	0
Lease Liability	1,393	1,598	1,686	1,826
Long term Provision	568	607	674	749
Total non current liabilities	1,961	2,204	2,360	2,575
Trade Payables	1,230	1,338	1,292	1,365
Lease Liability	530	546	576	624
Other Current Liabilities	3,045	3,041	3,313	3,619
Short term Provisions	492	525	584	649
Total Current Liabilities	5,297	5,450	5,765	6,257
Total liabilities	35,857	38,803	42,407	46,297
Property Plants and Equipments	1,541	1,611	1,649	1,650
Right of use of Assets	1,551	1,598	1,686	1,826
CWIP	16	16	16	16
Intangible Assets	88	121	152	182
Other current assets	4,686	4,677	5,174	5,733
Total Non-Current Assets	7,882	8,023	8,677	9,407
Current Assets				
Trade Receivables	9,715	9,695	10,910	12,277
Cash and Cash Equivalent	1,353	4,183	5,643	7,127
Bank Balance	14,711	14,711	14,711	14,711
Other current assets	2,196	2,191	2,466	2,775
Total Current Assets	27,975	30,780	33,730	36,890
Total Assets	35,857	38,803	42,407	46,297

Tata Elxsi Ltd.

Tata Elxsi Ltd.

Date	CMP (INR)	TP (INR)	Recommendation
14-Jul-25	6,066	4,965	SELL
21-Apr-25	4,901	5,093	HOLD
13-Jan-25	6,001	5,853	REDUCE
12-Oct-24	7,675	7,359	REDUCE
11-Jul-24	6,957	7,150	HOLD
25-Apr-24	7,030	7,536	ACCUMULATE

Rating Legend (Expected over a 12-month period)

Our Rating	Upside
Buy	More than 15%
Accumulate	5% – 15%
Hold	0 – 5%
Reduce	-5% – 0
Sell	Less than – 5%

ANALYST CERTIFICATION:

I, **Ishank Gupta** (CA), Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect my views about the subject issuer(s) or securities. I also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

Terms & Conditions and other disclosures:

DRChoksey FinServ Private Limited (hereinafter referred to as DCFPL) is a registered member of SEBI as a Research Entity vide Registration No. INH000011246 under SEBI (Research Analyst) Regulations, 2014, Portfolio Managers Entity vide Registration No. INP000007906 under SEBI (PORTFOLIO MANAGERS) Regulations, 2020 & Investment Adviser Entity vide Registration No. INA000017903 under SEBI (INVESTMENT ADVISERS) REGULATIONS, 2013.

The information and opinions in this report have been prepared by DCFPL and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of DCFPL. While we would endeavor to update the information herein on a reasonable basis, DCFPL is not under any obligation to update the information. Also, there may be regulatory, compliance or other reasons that may prevent DCFPL from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or DCFPL policies, in circumstances where DCFPL might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. DCFPL will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. DCFPL accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. Our employees in sales and marketing team, dealers and other professionals may provide oral or written market commentary or trading strategies that reflect opinions that are contrary to the opinions expressed herein, in reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

We submit that no material disciplinary action has been taken on DCFPL and its associates (Group Companies) by any Regulatory Authority impacting Equity Research Analysis activities.

DCFPL prohibits its associate, analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analyst covers.

DCFPL or its associates (Group Companies) collectively or its research analyst, or relatives do not hold any financial interest/beneficial ownership of more than 1% (at the end of the month immediately preceding the date of publication of the research report) in the company covered by Analyst, and has not been engaged in market making activity of the company covered by research analyst.

It is confirmed that, I, **Ishank Gupta** Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months. Compensation of our Research Analysts is not based on any specific brokerage service transactions.

DCFPL or its Associates (Group Companies) have not managed or co-managed public offering of securities for the subject company in the past twelve months.

DCFPL or its associates (Group Companies) collectively or its research analyst, or relatives might have received any commission/compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of brokerage services or specific transaction or for products and services other than brokerage services.

DCFPL or its associates (Group Companies) collectively or its research analyst, or relatives might have received any commission/compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report other than investment banking or merchant banking or brokerage services from the subject company

DCFPL encourages the practice of giving independent opinion in research report preparation by the analyst and thus strives to minimize the conflict in preparation of research report. DCFPL or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither DCFPL nor Research Analysts his associate or his relative, have any material conflict of interest at the time of publication of this report.

It is confirmed that **Ishank Gupta**, Research Analyst do not serve as an officer, director or employee of the companies mentioned in the report.

DCFPL or its associates (Group Companies) or its research analyst has may been engaged in market making activity for the subject company.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other Jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject DCFPL and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform them of and to observe such restriction.

The securities quoted are for illustration only and are not recommendatory.

DCFPL (Research Entity) and its research analysts uses Artificial Intelligence tools.

DCFPL and its Research analysts shall be solely responsible for the security, confidentiality and integrity of the client data, use of any other information or data for research services, research services based on output of Artificial Intelligence tools and compliance with any law for the time being in force.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other Jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject DCFPL and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform them of and to observe such restriction.

Investment in securities are subject to market risks, read all the documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

Please send your feedback to research.retail@devenchoksey.com

DRChoksey FinServ Private Limited

CIN Number -U67100MH2020PTC352816

Registered Office and Corporate Office:

5th Floor Abhishek Building, Behind Monginis Cake Factory, Off New Link Road, Andheri West, Mumbai-400058